Isatuximab Pharmacovigilance Knowledge Assessment

Apply the broadest mechanism-based label whenever a biologically plausible pathway exists Reconstruct exposure and disease context, document competing causes, assess uncertainty and preserve source-to-decision traceability Focus exclusively on whether the event appears in the product information Treat all events during combination therapy as attributable to the most recently administered medicine

Because the antibody cannot produce any adverse effects when given with another medicine Because the disease, co-administered medicines and treatment phase may independently cause or amplify the same event Because combination regimens make product batch information unnecessary Because causality is determined solely by the number of medicines taken

A chimeric IgG1 monoclonal antibody targeting CD38 and used in multiple-myeloma combination regimens A small-molecule kinase inhibitor used as monotherapy for solid tumours A live biological vaccine administered intramuscularly for infection prevention A non-biological analgesic whose principal risk is dose-dependent organ toxicity

Classify the event immediately as an infection because fever is present Classify the event immediately as an infusion reaction because it occurred during administration Assess infusion chronology, phenotype, vital signs, infection evidence, premedication and alternative causes Exclude an isatuximab relationship because fever is not a molecularly specific finding

CD38 targeting proves that any infection or laboratory abnormality is caused by isatuximab CD38 targeting is irrelevant once an event has been reported CD38 targeting provides a biologically plausible hypothesis that must be tested against timing, findings and alternatives CD38 targeting means that only immune-mediated events should be assessed

It can interfere with indirect antiglobulin testing and requires appropriate blood-bank communication It eliminates the need for pre-transfusion blood-group testing It proves that every post-transfusion reaction is caused by isatuximab It affects only product storage and has no laboratory relevance

As a routine diagnostic test that should always be performed As evidence that is irrelevant to causality As potentially informative when it occurs in routine care, but not something to undertake solely for diagnosis As definitive proof of causality regardless of the clinical phenotype

Pool all cases across indications, treatment lines and regimens to maximise the count Stratify by relevant clinical context such as regimen, treatment phase, disease severity, baseline risk and duration Use only preferred-term frequencies without reviewing case narratives Exclude cases with concomitant medicines because they cannot contribute to a signal

The increase proves a new causal effect of isatuximab The increase should be assessed in relation to changing populations, treatment lines, reporting stimulation, background disease and exposure denominators The increase should be ignored because infections were known during development The increase proves that all combination partners have the same risk

The antibody has no biological activity after administration Persistent pharmacodynamic activity may continue after dosing has stopped Interruption always worsens the adverse event All adverse events are necessarily irreversible